SCHEDULE 13G: Affinity Healthcare Fund Discloses 7.75% Stake in Lexeo Therapeutics
Beneficial Ownership Report
Affinity Healthcare Fund, LP and its advisor, Affinity Asset Advisors, LLC, have disclosed a 7.75% beneficial ownership stake in Lexeo Therapeutics, Inc., totaling 4,252,005 shares of common stock.
Summary
- Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC have reported a beneficial ownership of 4,252,005 shares of Lexeo Therapeutics, Inc. common stock.
- This stake represents 7.75% of Lexeo Therapeutics' outstanding common stock.
- The ownership includes warrants to purchase 867,302 shares of common stock exercisable within the next sixty days.
- The percentage is calculated based on 54,854,419 shares outstanding as of May 28, 2025, which includes shares from a recent private placement.
- Affinity Asset Advisors, LLC, as the investment manager, exercises investment discretion over these securities.
- Both entities share voting and dispositive power over the 4,252,005 shares.
Sentiment
Score: 6
Explanation: The disclosure of a significant institutional investment is generally viewed as a positive signal of confidence in the company, although the filing itself is purely factual and does not contain performance data.
Positives
- A significant institutional investor, Affinity Healthcare Fund, LP, has taken a substantial 7.75% stake in Lexeo Therapeutics, potentially signaling confidence in the company's future prospects.
- The investment includes warrants, indicating a potential for increased future ownership.
Negatives
- No specific negative information regarding Lexeo Therapeutics' operations or financial performance is disclosed in this beneficial ownership report.
Risks
- The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer, which is a standard declaration for a Schedule 13G filing.
Future Outlook
The document does not contain any forward-looking statements or guidance from Lexeo Therapeutics, Inc. or the reporting persons regarding the issuer's future performance.
Industry Context
This filing indicates a significant investment by a healthcare-focused fund in a biotechnology company, Lexeo Therapeutics, Inc. While the filing itself does not provide broader industry analysis, such an investment suggests that institutional investors are actively deploying capital into the biotech sector, potentially seeking opportunities in companies like Lexeo.
Comparison to Industry Standards
- This Schedule 13G filing is a standard regulatory disclosure for an investor acquiring more than 5% of a company's stock with a passive investment intent.
- It does not provide specific comparable company or project results, but the acquisition of a 7.75% stake by a healthcare-focused fund is a notable event within the biotech investment landscape, indicating a significant capital allocation decision by Affinity Healthcare Fund, LP.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investment may be perceived positively, potentially boosting investor confidence and share price.
- Company (Lexeo Therapeutics): The private placement indicates successful capital raising, which can support ongoing operations and strategic initiatives.
Next Steps
- The document does not specify any future actions, events, or milestones for Lexeo Therapeutics, Inc. or the reporting persons beyond the filing of this statement.
Key Dates
| Date | Description |
|---|---|
| 2025-05-12 | Date as of which 33,196,997 shares of Common Stock of the Issuer were outstanding, as per Issuer's Form 10-Q. |
| 2025-05-15 | Date Lexeo Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-05-27 | Date Lexeo Therapeutics, Inc. filed its Current Report on Form 8-K with the SEC, detailing a private placement. |
| 2025-05-28 | Date of event which requires filing of this statement; also the date of a private placement where 20,790,120 shares were issued. |
| 2025-06-04 | Date as of which Affinity Healthcare Fund, LP beneficially owned the reported shares; also the signature date of the Schedule 13G filing. |
Keywords
Lexeo Therapeutics, Affinity Healthcare Fund, Affinity Asset Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Private Placement, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.